Ocera Therapeutics, Inc. Completes Enrollment In FHAST1, A Pivotal Phase 3 Clinical Trial In Fistulizing Crohn’s Disease
Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases announced today that it has completed the patient enrollment of its Phase 3 study in fistulizing Crohn’s disease.
